Detalhe da pesquisa
1.
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Gynecol Oncol
; 171: 151-158, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36905875
2.
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
Gynecol Oncol
; 176: 16-24, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37418832
3.
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Gynecol Oncol
; 157(1): 161-166, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924334
4.
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
Gynecol Oncol
; 155(3): 393-399, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31653510
5.
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol
; 153(2): 335-342, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30827726
6.
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
Gynecol Oncol
; 150(2): 274-281, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29804638
7.
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Gynecol Oncol
; 148(1): 174-180, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29132872
8.
Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Cancer
; 123(7): 1144-1155, 2017 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27926776
9.
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 145(2): 291-297, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28285845
10.
FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 145(2): 366-373, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28314589
11.
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Gynecol Oncol
; 146(1): 137-145, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28483269
12.
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Gynecol Oncol
; 144(1): 96-100, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28094040
13.
A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 144(1): 101-106, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28029447
14.
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 147(2): 283-290, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28802766
15.
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 145(2): 236-242, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28341300
16.
Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 147(3): 648-653, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28969912
17.
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 144(3): 459-467, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28089376
18.
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 140(2): 264-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603970
19.
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Int J Gynecol Cancer
; 26(1): 125-32, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26397159
20.
Minority participation in Gynecologic Oncology Group (GOG) Studies.
Gynecol Oncol
; 138(2): 441-4, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26013697